《抗肿瘤药物治疗期间肾损伤管理临床实践指南(2022)》解读(三):抗肿瘤药物治疗患者的肾功能评估(第2部分)  

Interpretation of Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022(Ⅲ):evaluation of kidney function in patients undergoing anticancer drug therapy(Part 2)

作　　者：王伊娜[1] 左力[1] 燕宇[1] Wang Yina;Zuo Li;Yan Yu(Renal Division,Peking University People′s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院肾内科,北京100044

出　　处：《药物不良反应杂志》2024年第7期385-389,共5页Adverse Drug Reactions Journal

基　　金：北京大学人民医院研究与发展基金(RDJP2022‑31,RDL2022‑08)。

摘　　要：抗肿瘤药物因其细胞毒性、血管毒性和免疫毒性等特征,可能比其他药物更容易导致肾损伤。充分认识抗肿瘤药物相关肾损伤的临床表现和危险因素,合理评估疾病严重程度,以更好地调整抗肿瘤治疗方案,是抗肿瘤治疗的重要内容。为此,日本肾脏病学会、日本临床肿瘤学会、日本医学肿瘤学会和日本肾脏病药物治疗学会共同制订的《抗肿瘤药物治疗期间肾损伤管理临床实践指南(2022)》中对肿瘤患者在抗肿瘤药物治疗后发生药物性肾损伤的定义、评估方法、主要临床表现和危险因素进行了专门的论述。本文对这部分内容进行解读,以期更有效地指导临床实践。Due to the characteristics of cytotoxicity,vascular toxicity,and immunotoxicity,anticancer drugs may be more likely to cause kidney injury than other drugs.It is an important content in antitumor treatment to fully understand the clinical manifestations and risk factors of anticancer drug‑related renal injury,and evaluate the disease severity reasonably,so as to better adjust the anticancer schedule.Thus,the Japanese Society of Nephrology,Japan Society of Clinical Oncology,Japanese Society of Medical Oncology,and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 and made special discussions and suggestions on the definition,evaluation methods,main clinical manifestations,and risk factors of drug‑induced kidney injury in cancer patients after receiving anticancer drug treatments.This article interprets this part of the content in order to make more effective guidance in clinical practice.

关 键 词：抗肿瘤药物 急性肾损伤 肾功能不全 指南 解读 

分 类 号：R979.1[医药卫生—药品]